KEY TAKEAWAYS
- ROP is abnormal retinal vascular development in preterm infants and a leading cause of preventable childhood blindness — driven by low gestational age, low birth weight, and oxygen exposure.
- It's a two-phase disease: early vaso-obliteration (relative hyperoxia after birth), then vaso-proliferation (the avascular retina becomes hypoxic → VEGF surge → neovascularization).
- Describe every exam in ICROP terms: zone (I–III, location), stage (1–5, severity at the vascular border), and plus disease (vessel dilation/tortuosity = activity).
- Treat "type 1" ROP; observe "type 2." Type 1 = zone I any stage with plus, zone I stage 3 without plus, or zone II stage 2/3 with plus.
- Treatment options are laser photocoagulation and intravitreal anti-VEGF — anti-VEGF (e.g., bevacizumab) is especially advantageous for zone I / aggressive posterior disease, but requires prolonged follow-up for late reactivation.
- Screen by protocol (typically ≤30 weeks GA or ≤1500 g, plus selected higher-risk larger infants) and titrate oxygen to reduce disease.
1. Clinical Overview
Clinical Overview
The retina vascularizes late in gestation, growing outward from the optic disc and reaching the periphery near term. Preterm birth interrupts this process and exposes the immature retina to an extrauterine environment — relatively hyperoxic and lacking the placental growth-factor milieu. The result is a disease of disordered retinal angiogenesis that, in its severe forms, produces neovascularization, fibrosis, traction, and retinal detachment — potentially blinding, yet largely preventable and treatable when caught in time.
Because early ROP is asymptomatic and only a trained examiner can detect it, systematic screening of at-risk infants is the linchpin. Treatment thresholds are defined precisely (ETROP), and the therapeutic landscape has expanded from laser alone to include anti-VEGF agents, which have changed management of the most posterior, aggressive disease.
2. Definitions (ICROP)
| Component | Meaning |
|---|
| Zone I | Posterior circle centered on the disc (radius = 2× disc–fovea distance) — most posterior, most dangerous. |
| Zone II | From the edge of zone I to the nasal ora serrata. |
| Zone III | Remaining temporal crescent — most anterior, least severe. |
| Stage 1 | Demarcation line between vascular and avascular retina. |
| Stage 2 | Ridge (the line acquires height/width). |
| Stage 3 | Extraretinal fibrovascular proliferation (neovascularization) at the ridge. |
| Stage 4 | Partial retinal detachment (4A extrafoveal; 4B involving fovea). |
| Stage 5 | Total retinal detachment. |
| Plus disease | Dilation + tortuosity of posterior pole vessels — marker of activity/severity (pre-plus = intermediate). |
| Aggressive (posterior) ROP (A-ROP/AP-ROP) | Severe, rapidly progressive, posterior disease that can bypass classic staging. |
3. Pathophysiology (why oxygen matters both ways)
Pathophysiology (why oxygen matters both ways)
Phase 1 — vaso-obliteration (roughly birth to ~30–32 weeks PMA):
- After preterm birth, the retina experiences relative hyperoxia (compared with the low-oxygen intrauterine state), which suppresses VEGF and IGF-1 → normal vessel growth halts and some vessels regress → a peripheral avascular retina.
Phase 2 — vaso-proliferation (roughly after ~32 weeks PMA):
- As the infant grows, the metabolically demanding but avascular retina becomes hypoxic → a surge in VEGF → disordered neovascularization at the vascular/avascular junction → ridge, extraretinal proliferation, and — if unchecked — fibrosis, traction, and detachment.
Risk factors: low gestational age and birth weight (dominant), oxygen exposure and fluctuation/hyperoxia, poor postnatal weight gain (low IGF-1), sepsis, and general illness severity.
4. Screening
Screening
Who (typical AAP/AAO/AAPOS criteria — verify locally):
- All infants ≤30 weeks' gestational age or ≤1500 g birth weight, plus selected infants >1500 g / >30 weeks with an unstable clinical course thought to be at risk.
When (first exam by PMA/chronological age):
- Timed so as not to miss treatment-requiring disease — commonly the more preterm the infant, the later the PMA of first exam (e.g., very early gestations examined around ~31 weeks PMA; more mature preterms at ~4 weeks of chronological age). Follow your published screening schedule.
How:
- Dilated indirect ophthalmoscopy by a qualified ophthalmologist, or wide-field digital retinal imaging / telemedicine with expert grading.
- Follow-up interval (≤1 week, 1–2 weeks, 2 weeks, 2–3 weeks) is set by the worst zone/stage/plus findings — more posterior/active disease → shorter interval.
5. Treatment (ETROP framework)
Treatment (ETROP framework)
Type 1 ROP → treat (typically within ~48–72 h):
- Zone I, any stage, WITH plus disease
- Zone I, stage 3, WITHOUT plus disease
- Zone II, stage 2 or 3, WITH plus disease
Type 2 ROP → observe closely (treat if it progresses to type 1):
- Zone I, stage 1–2, without plus
- Zone II, stage 3, without plus
Treatment modalities
- Laser photocoagulation — ablates the peripheral avascular retina; long-standing standard; effective but causes peripheral visual-field loss and myopia, and can be difficult in very posterior disease.
- Intravitreal anti-VEGF (e.g., bevacizumab, ranibizumab, aflibercept) — blocks the VEGF drive:
- Advantage in zone I / aggressive posterior disease (BEAT-ROP showed lower recurrence vs laser for zone I stage 3+), allows continued peripheral vascularization, and less myopia.
- Caveats: late reactivation/recurrence requires prolonged, vigilant follow-up (months); theoretical systemic VEGF suppression (effects on developing brain/organs uncertain); optimal agent/dose still evolving. AAP advises detailed informed consent for anti-VEGF.
- Advanced disease (stage 4–5): vitreoretinal surgery (scleral buckle/vitrectomy) — outcomes are guarded.
6. Monitoring
Monitoring
- Continue examinations until the retina is fully vascularized or the risk window has passed (per exit criteria).
- After treatment: early post-treatment exams to detect complications, then regular surveillance for reactivation — especially prolonged follow-up after anti-VEGF (late recurrences occur weeks–months later).
- Long-term ophthalmologic follow-up for refractive error (myopia), strabismus, amblyopia, and late retinal complications.
7. Complications
Complications
- Progression to retinal detachment (stage 4–5) → blindness.
- Refractive errors (high myopia — more with laser), strabismus, amblyopia, anisometropia.
- Late reactivation after anti-VEGF; persistent peripheral avascular retina.
- Lifelong risk of retinal tears/detachment in treated eyes.
8. Prevention
Prevention
- Judicious oxygen management — target the recommended SpO₂ range and avoid hyperoxia and wide saturation swings (a key modifiable driver).
- Optimize nutrition/postnatal growth (IGF-1).
- Prevent/treat sepsis and comorbidities.
- Ensure reliable screening and follow-up — a systems/process safeguard as important as any drug.
9. Safety Warnings
Safety Warnings
- ⚠️ A missed or late screening exam can cost a child's sight — screening logistics are a patient-safety issue.
- ⚠️ Treat type 1 promptly (within ~48–72 h) — treatment-requiring ROP progresses fast.
- ⚠️ Anti-VEGF demands prolonged follow-up — late reactivation is real; don't discharge from surveillance early.
- ⚠️ Oxygen is a double-edged sword — necessary, but hyperoxia/fluctuations drive ROP.
- ⚠️ Obtain detailed informed consent for anti-VEGF (systemic effects uncertain).
- ⚠️ Aggressive posterior ROP can bypass classic staging — recognize and treat urgently.
10. Common Mistakes
Common Mistakes
- Missing or delaying the first screening exam, or losing an infant to follow-up.
- Misapplying ETROP type 1 vs type 2 thresholds (over- or under-treating).
- Discharging anti-VEGF-treated infants from surveillance too soon (late reactivation).
- Loose oxygen targeting (hyperoxia, wide swings).
- Failing to recognize aggressive posterior ROP.
- Neglecting long-term refractive/strabismus follow-up.
- Omitting informed consent discussion for anti-VEGF.
11. Clinical Pearls
Clinical Pearls
- 💡 Zone > stage > plus for danger — the more posterior, the worse.
- 💡 Plus disease is the activity flag — it converts "observe" into "treat."
- 💡 Two phases, one culprit: oxygen suppresses then hypoxia unleashes VEGF.
- 💡 Anti-VEGF shines in zone I / posterior disease — but the follow-up tail is long.
- 💡 Laser trades peripheral retina (and some field/myopia) for stopping the disease.
- 💡 Screening reliability is a treatment — a robust process prevents blindness.
12. Summary Table
Summary Table
| Domain | Bottom line |
|---|
| What | Disordered retinal angiogenesis of prematurity; preventable childhood blindness |
| Phases | 1) vaso-obliteration (relative hyperoxia) → 2) vaso-proliferation (hypoxia → VEGF → neovascularization) |
| Classify | Zone I–III · Stage 1–5 · plus disease (± A-ROP) |
| Screen | ≤30 wk GA or ≤1500 g (+ selected higher-risk); timed first exam; interval by findings |
| Treat (type 1) | Zone I any stage + plus; zone I stage 3 no plus; zone II stage 2/3 + plus |
| Observe (type 2) | Zone I stage 1–2 no plus; zone II stage 3 no plus |
| Modalities | Laser (peripheral ablation) or anti-VEGF (zone I/posterior; long follow-up); surgery for stage 4–5 |
| Prevent | Judicious oxygen (avoid hyperoxia/swings); growth/nutrition; reliable screening |
| Follow-up | Until vascularized/exit criteria; prolonged after anti-VEGF; lifelong refractive/retinal risk |
13. Step-by-Step Bedside Algorithm
PRETERM INFANT ≤30 wk GA or ≤1500 g (or selected higher-risk >1500 g)
│
PREVENTION: titrate O₂ to target (avoid hyperoxia/swings); optimize growth; treat sepsis
│
▼
SCHEDULED SCREENING EXAM (dilated indirect ophthalmoscopy / wide-field imaging)
│
▼
CLASSIFY (ICROP): ZONE (I–III) · STAGE (1–5) · PLUS disease · (A-ROP?)
│
▼
Apply ETROP thresholds
│
TYPE 1 (zone I any stage + plus │ zone I stage 3 no plus │ zone II stage 2/3 + plus)
│ → TREAT within ~48–72 h
│ • Laser photocoagulation, OR
│ • Intravitreal anti-VEGF (favored for zone I / posterior; informed consent)
│ → early post-Rx exams; then SURVEILLANCE for reactivation
│ (prolonged, especially after anti-VEGF)
│
TYPE 2 → OBSERVE closely at short intervals; treat if progresses to type 1
│
Immature/incomplete vascularization, no treatment-requiring disease
│ → continue exams per interval until vascularized / exit criteria
▼
STAGE 4–5 (detachment)? → vitreoretinal surgery (guarded prognosis)
│
▼
LONG-TERM ophthalmology follow-up (myopia, strabismus, amblyopia, late retinal risk)
14. References to Verify
Confirm each against the primary source before clinical or published use. Screening cut-offs and schedules are country/society-specific.
- 1.Classification: International Classification of Retinopathy of Prematurity — ICROP (Third Edition, 2021). (Verify zone/stage/plus definitions and A-ROP.)
- 2.Treatment thresholds: Early Treatment for Retinopathy of Prematurity (ETROP) Cooperative Group. Arch Ophthalmol. 2003 (type 1/type 2). (Verify.)
- 3.Screening: AAP/AAO/AAPOS. Screening Examination of Premature Infants for Retinopathy of Prematurity (Policy Statement — most current revision). (Verify age/weight criteria and schedule.)
- 4.Anti-VEGF (bevacizumab): Mintz-Hittner HA, et al. Efficacy of Intravitreal Bevacizumab for Stage 3+ ROP (BEAT-ROP). NEJM. 2011;364:603–615. (Zone I benefit — verify.)
- 5.Anti-VEGF (ranibizumab): RAINBOW trial. Lancet. 2019. (Verify.)
- 6.Oxygen targets: SUPPORT / BOOST-II / NeOProM saturation-target evidence relevant to ROP. (Verify current target range.)